Clinical trials · New York
Small Cell Lung Carcinoma clinical trials in New York
We’re tracking 136 recruiting small cell lung carcinoma studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT06769126RecruitingPhase 2
Personalized treatment study for extensive stage small cell lung cancer
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
Webster, New YorkAges 18 years+ - NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Shirley, New YorkAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT06957314Recruiting
Hospital-at-home for people receiving Tarlatamab
This study tests giving hospital-type care at home for people with extensive-stage small cell lung cancer who are receiving the drug Tarlatamab. It aims to see if patients can safely receive their treatment at home instead of in the hospital.
Uniondale, New YorkAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
New York, New YorkAges 18 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
New York, New YorkAges 18 years+ - NCT04804644RecruitingPhase 3
Memory-sparing radiation for brain metastases in small cell lung cancer
This study tests whether focusing high-dose radiation only on brain tumor spots, while avoiding the hippocampus (a brain area important for memory), helps protect memory and thinking compared with standard whole-brain radiation. It’s for people with small cell lung cancer that has spread to the brain.
The Bronx, New YorkAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Lake Success, New YorkAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT07535463RecruitingPhase 1/Phase 2
Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Harrison, New YorkAges 18 years+ - NCT07619339RecruitingPhase 1
Tepotinib and Ivonescimab for MET-Driven Lung Cancer
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
Uniondale, New YorkAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
New York, New YorkAges 18 years+ - NCT06807632RecruitingPhase 1
Study of two drugs for extensive-stage small cell lung cancer
This trial tests a new combination of two drugs (valemetostat and atezolizumab) for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if adding valemetostat can keep the cancer from growing longer.
Commack, New YorkAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Commack, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Buffalo, New YorkAges Any age - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
New York, New YorkAges 18 years+ - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
New York, New YorkAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Lake Success, New YorkAges 18–99 - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
New York, New YorkAges 18 years+
Small Cell Lung Carcinoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting small cell lung carcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- NYU Langone Health · 4 studies
- START Center for Cancer Research · 3 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 2 studies
What taking part in a small cell lung carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Small Cell Lung Carcinoma trials in other states
Common questions
- Are there small cell lung carcinoma clinical trials in New York?
- Yes. We're currently tracking 136 recruiting small cell lung carcinoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung carcinoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung carcinoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.